Lakefront Biotherapeutics (LKFT) Non-Current Deferred Tax Liability (2014 - 2025)

Lakefront Biotherapeutics (LKFT) has reported Non-Current Deferred Tax Liability for 5 consecutive years, with $20.2 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Non-Current Deferred Tax Liability changed N/A year-over-year to $20.2 million; the TTM figure through Jun 2025 stood at $20.2 million (changed N/A YoY), while the FY2024 annual figure was $22.1 million, down 13.08% from the prior year.
• Non-Current Deferred Tax Liability grew to $20.2 million in Q2 2025 per LKFT's latest filing, from $19.7 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $27.6 million in Q3 2023 and bottomed at $19.7 million in Q1 2025.
• Historically, Non-Current Deferred Tax Liability has averaged $22.7 million across 4 years, with a median of $22.1 million in 2024.
• Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability climbed 23.56% — and 2025, when it declined 20.26%.
• Lakefront Biotherapeutics' Non-Current Deferred Tax Liability stood at $20.6 million in 2022, then gained by 23.56% to $25.4 million in 2023, then dropped by 13.08% to $22.1 million in 2024, then retreated by 8.34% to $20.2 million in 2025.
• Business Quant data shows LKFT's Non-Current Deferred Tax Liability at $20.2 million in Q2 2025, $19.7 million in Q1 2025, and $22.1 million in Q4 2024.